Evotec SE (EVO) Liabilities and Shareholders Equity (2009 - 2026)

Evotec SE (EVO) reported Liabilities and Shareholders Equity of $1.9 million for Q1 2026, down 6.16% on a YoY basis from $2.0 million in Q1 2025, and up 96125.58% sequentially from $1995.1 in Q4 2025.

Evotec SE (EVO) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends

Evotec SE (EVO) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $1.9 million in Q1 2026.

  • For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 6.16% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (down 100.0% YoY), and the FY2025 full-year result was $1995.1, down 100.0% from the prior year.
  • Liabilities and Shareholders Equity rose to $1.9 million in Q1 2026, from $1995.1 in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $2452.3 billion in Q1 2022 to a low of $1995.1 in Q4 2025.
  • A 5-year average of $586.7 billion and a median of $22.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Across the five-year window, Liabilities and Shareholders Equity soared 4610.0% in 2024 and sank 100.0% in 2025, its largest moves.
  • Tracing EVO's Liabilities and Shareholders Equity over 5 years: stood at $55.0 million in 2022, then declined by 21.06% to $43.4 million in 2023, then soared by 4610.0% to $2.0 billion in 2024, then slumped by 100.0% to $1995.1 in 2025, then jumped by 96125.58% to $1.9 million in 2026.
  • Business Quant data shows EVO's Liabilities and Shareholders Equity at $1.9 million in Q1 2026, $1995.1 in Q4 2025, and $2.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 40.04 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 6.71 Bn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - 25.35 Mn
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 13.22 Bn
10 Evotec SE 339.17 Mn 338.65 Mn - 1.92 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.92 Mn
Dec 31, 2025 1,995.11
Sep 30, 2025 2.07 Mn
Jun 30, 2025 2.05 Mn
Mar 31, 2025 2.05 Mn
Dec 31, 2024 2.04 Bn
Sep 30, 2024 2,186.35 Bn
Mar 31, 2024 2,399.39 Bn
Dec 31, 2023 43.39 Mn
Dec 31, 2022 54.97 Mn
Sep 30, 2022 2.28 Mn
Mar 31, 2022 2,452.33 Bn
Dec 31, 2021 29.12 Mn
Sep 30, 2021 2,084.80 Bn
Dec 31, 2020 23.00 Mn
Dec 31, 2019 12.69 Mn
Sep 30, 2010 230,107.36
Jun 30, 2010 192,993.83
Mar 31, 2010 200.13 Mn
Dec 31, 2009 216,487.76